Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2012
08/09/2012US20120202813 Triazole compounds that modulate hsp90 activity
08/09/2012US20120202812 Heteroaryls and uses thereof
08/09/2012US20120202809 Novel n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as pkc kinase inhibitors
08/09/2012US20120202805 PI3K (delta) SELECTIVE INHIBITORS
08/09/2012US20120202802 Spirocyclic compounds as modulators of chemokine receptor activity
08/09/2012US20120202801 Methods for treating breast cancer
08/09/2012US20120202800 Dual small molecule inhibitors of cancer and angiogenesis
08/09/2012US20120202799 Condensed Azepine Derivatives As Bromodomain Inhibitors
08/09/2012US20120202790 [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
08/09/2012US20120202789 Compositions and methods for the treatment of cancer
08/09/2012US20120202785 Heterocyclic compounds and methods of use
08/09/2012US20120202782 Compounds and compositions as itpkb inhibitors
08/09/2012US20120202776 Phosphorus derivatives as kinase inhibitors
08/09/2012US20120202774 Acyloxy- and phosphoryloxy-butadiene-fe(co)3 complexes as enzyme-triggered co-releasing molecules
08/09/2012US20120202772 Cyclodextrin-based polymers for therapeutic delivery
08/09/2012US20120202765 Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds
08/09/2012US20120202764 Low molecular weight pharmacological activity modulators
08/09/2012US20120202763 Methods for treating cancer and non-neoplastic conditions
08/09/2012US20120202762 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
08/09/2012US20120202761 Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt
08/09/2012US20120202760 Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
08/09/2012US20120202758 Core 2glcnac-t inhibitors
08/09/2012US20120202756 Use of prodrugs to avoid gi mediated adverse events
08/09/2012US20120202750 Inhibitors of iap
08/09/2012US20120202749 Secreted frizzled related protein, sfrp, fragments and methods of use thereof
08/09/2012US20120202743 SUSTAINED RELEASE FORMULATIONS COMPRISING GnRH ANALOGUES
08/09/2012US20120202733 Inhibition of trem receptor signaling with peptide variants
08/09/2012US20120202208 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
08/09/2012US20120202206 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
08/09/2012US20120201903 Cytoprotective or therapeutic plant composition
08/09/2012US20120201874 Liposome Having Inner Water Phase Containing Sulfobutyl Ether Cyclodextrin Salt
08/09/2012US20120201872 Liposomes comprising a calcium phosphate-containing precipitate
08/09/2012US20120201867 Drug delivery from embolic agents
08/09/2012US20120201859 Drug Delivery Systems and Use Thereof
08/09/2012US20120201848 Isolation of a virus related to canine parvovirus-2 from a raccoon
08/09/2012US20120201843 Cyp1b1 nucleic acids and methods of use
08/09/2012US20120201841 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
08/09/2012US20120201838 Method for screening anticancer agent or sip1/zeb2 inhibitor using integrin alpha 5
08/09/2012US20120201837 Use of eif3m for the diagnosis and treatment of cancer
08/09/2012US20120201836 Methods and compositions for modulating t cell and/or b cell activation
08/09/2012US20120201832 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
08/09/2012US20120201828 Antibodies that specifically bind to the epha2 receptor
08/09/2012US20120201824 Compositions and Methods for Inhibiting an Oncogenic Protein to Enhance Immunogenicity
08/09/2012US20120201823 April antagonists and methods of use
08/09/2012US20120201822 Tumor treatment
08/09/2012US20120201820 Immunological compositions as cancer therapeutics
08/09/2012US20120201818 Treatment of multiple sclerosis
08/09/2012US20120201817 Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
08/09/2012US20120201810 Use of Anti-DKK-1 Monoclonal Antibodies for the Treatment of Liver Cancer
08/09/2012US20120201809 Multifunctional antibody conjugates
08/09/2012US20120201808 Stem Cell Fusion Model of Carcinogenesis
08/09/2012US20120201801 Topical co-enzyme q10 formulations and methods of use
08/09/2012US20120201800 Methods and Devices for Sustained In-Vivo Release Of an Active Agent
08/09/2012US20120201799 Devices, systems and methods for cell modification
08/09/2012US20120201797 Agent for reducing risk of developing cancer
08/09/2012US20120201790 Promoters exhibiting endothelial cell specificity and methods of using same
08/09/2012US20120201753 Methods and compositions related to targeting wounds, regenerating tissue, and tumors
08/09/2012US20120201752 Foxc1 antibodies and methods of their use
08/09/2012US20120201751 Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44
08/09/2012US20120201750 Serum biomarkers for melanoma metastasis
08/09/2012US20120201749 NP-1 Antagonists and Their Therapeutic Use
08/09/2012US20120201748 Coacervate having an ionic polymer mixed with the adhesive protein of a mussel or of a species of the variome thereof
08/09/2012US20120201747 System and Method for Diagnosis and Treatment
08/09/2012DE102011011040A1 (5s,8s)-3-(4'-Chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-on (Verbindung A) zur Therapie (5S, 8s) -3- (4'-chloro-3'-fluoro-4-methylbiphenyl-3-yl) -4-hydroxy-8-methoxy-1-azaspiro [4.5] dec-3-en-2- one (Compound A) for the therapy
08/09/2012DE102011001380B3 Composition, useful in the reconstitution of the immune defense of humans in the context of bone marrow transplantation, and for treating cancer, preferably leukemia, comprises a cell population obtained from bone marrow or blood
08/09/2012CA2826251A1 Psa capture agents, compositions, methods and preparation thereof
08/09/2012CA2826186A1 Human antibodies and antibody-drug conjugates against cd74
08/09/2012CA2826144A1 Foxc1 antibodies and methods of their use
08/09/2012CA2826051A1 7-azaindole derivatives
08/09/2012CA2825990A1 Anti-tace antibody molecules and their uses
08/09/2012CA2825969A1 Dosing for treatment with anti-egfl7 antibodies
08/09/2012CA2825926A1 Cellulose-based nanoparticles for drug delivery
08/09/2012CA2825884A1 Ubiquitin interacting motif peptides as cancer therapeutics
08/09/2012CA2825786A1 Externally-used drug for treating skin disorder and method for producing same
08/09/2012CA2825605A1 Novel heterocyclic derivatives
08/09/2012CA2825599A1 Hdac inhibitors and therapeutic methods using the same
08/09/2012CA2825279A1 New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
08/09/2012CA2825165A1 Therapeutic or prophylactic agent for cachexia
08/09/2012CA2824092A1 Methods of using alk inhibitors
08/09/2012CA2823994A1 Combinations comprising macitentan for the treatment of glioblastoma multiforme
08/09/2012CA2823870A1 Inhibitors of the interaction of the sigma-1 receptor with herg for use in the treatment of cancer
08/09/2012CA2817841A1 1,4 oxazines as bace1 and/or bace2 inhibitors
08/09/2012CA2810515A1 Hydrated n-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof
08/09/2012CA2810507A1 Homo- and hetero-polyamino-acid derivatives of fullerene c60, method for producing same, and pharmaceutical compositions based on said derivatives
08/08/2012EP2484697A1 Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
08/08/2012EP2484693A1 Human serum amyloid-a3 antibody and use thereof
08/08/2012EP2484688A1 Peptide epoxyketones for proteasome inhibition
08/08/2012EP2484678A1 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
08/08/2012EP2484385A1 Composition for treatment of pancreatic cancer
08/08/2012EP2484374A1 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
08/08/2012EP2484372A1 Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
08/08/2012EP2484367A1 Agent for preventing adverse side effects of carcinostatic agent
08/08/2012EP2484363A1 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide
08/08/2012EP2484354A1 Antioxidant composition
08/08/2012EP2484353A1 Oral composition for alleviation of ultraviolet radiation-induced damage
08/08/2012EP2484344A2 Compositions and methods of using microspheres and non-ionic contrast agents
08/08/2012EP2483314A1 Bispecific binding molecules for anti-angiogenesis therapy
08/08/2012EP2483312A1 Antibodies that specifically bind to the epha2 receptor
08/08/2012EP2483280A1 New aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the met family
08/08/2012EP2483278A1 Benzoxazepin pi3k inhibitor compounds and methods of use
1 ... 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 ... 2211